MBBP client Shire Human Genetic Therapies, a global specialty biopharmaceutical company, announced last week that the U.S. Food and Drug Administration has approved their new drug VPRIV. VPRIV is a human cell line derived enzyme replacement therapy (ERT) meant to help treat Type 1 Gaucher disease. Shire’s drug has been prescribed to patients before its approval on an emergency basis for several months due to the shortage of Genzyme Corporation’s Cerezyme.
Good Company: A Morse Blog 